Proposed joint clinical assessment methodology would have rejected nearly 90% of the ATMPs currently authorized in the EU
Proposed joint clinical assessment methodology would have rejected nearly 90% of the ATMPs currently authorized in the EUWithout changes recognizing the unique characteristics of ATMPs, the EU’s new Joint Clinical Assessment will fail to deliver the next generation of transformative therapies to rare disease p...